

12-1-2022

The trend of disruption in the functional brain network topology of Alzheimer's disease

Alireza Fathian
Tarbiat Modares University

Yousef Jamali
Tarbiat Modares University

Mohammad Reza Raoufy
Tarbiat Modares University

Michael W. Weiner
University of California, San Francisco

Norbert Schuf
University of California, San Francisco

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/neurosci_inst_pubs

Citation of this paper:

Fathian, Alireza; Jamali, Yousef; Raoufy, Mohammad Reza; Weiner, Michael W.; Schuf, Norbert; Rosen, Howard J.; Miller, Bruce L.; Neylan, Thomas; Hayes, Jacqueline; Finley, Shannon; Aisen, Paul; Khachaturian, Zaven; Thomas, Ronald G.; Donohue, Michael; Walter, Sarah; Gessert, Devon; Sather, Tamie; Jiminez, Gus; Thal, Leon; Brewer, James; Vanderswag, Helen; Fleisher, Adam; Davis, Melissa; Morrison, Rosemary; Petersen, Ronald; Jack, Clifford R.; Bernstein, Matthew; Borowski, Bret; Gunter, Jef; and Senjem, Matt, "The trend of disruption in the functional brain network topology of Alzheimer's disease" (2022). *Neuroscience Institute Publications*. 99.
https://ir.lib.uwo.ca/neurosci_inst_pubs/99

Authors

Alireza Fathian, Yousef Jamali, Mohammad Reza Raoufy, Michael W. Weiner, Norbert Schuf, Howard J. Rosen, Bruce L. Miller, Thomas Neylan, Jacqueline Hayes, Shannon Finley, Paul Aisen, Zaven Khachaturian, Ronald G. Thomas, Michael Donohue, Sarah Walter, Devon Gessert, Tamie Sather, Gus Jiminez, Leon Thal, James Brewer, Helen Vanderswag, Adam Fleisher, Melissa Davis, Rosemary Morrison, Ronald Petersen, Clifford R. Jack, Matthew Bernstein, Bret Borowski, Jef Gunter, and Matt Senjem



OPEN

The trend of disruption in the functional brain network topology of Alzheimer's disease

Alireza Fathian¹, Yousef Jamali^{1,2✉}, Mohammad Reza Raoufy³ & for the Alzheimer's Disease Neuroimaging Initiative*

Alzheimer's disease (AD) is a progressive disorder associated with cognitive dysfunction that alters the brain's functional connectivity. Assessing these alterations has become a topic of increasing interest. However, a few studies have examined different stages of AD from a complex network perspective that cover different topological scales. This study used resting state fMRI data to analyze the trend of functional connectivity alterations from a cognitively normal (CN) state through early and late mild cognitive impairment (EMCI and LMCI) and to Alzheimer's disease. The analyses had been done at the local (hubs and activated links and areas), meso (clustering, assortativity, and rich-club), and global (small-world, small-worldness, and efficiency) topological scales. The results showed that the trends of changes in the topological architecture of the functional brain network were not entirely proportional to the AD progression. There were network characteristics that have changed non-linearly regarding the disease progression, especially at the earliest stage of the disease, i.e., EMCI. Further, it has been indicated that the diseased groups engaged somatomotor, frontoparietal, and default mode modules compared to the CN group. The diseased groups also shifted the functional network towards more random architecture. In the end, the methods introduced in this paper enable us to gain an extensive understanding of the pathological changes of the AD process.

Alzheimer's disease is an irreversible and progressive brain disorder that is the fifth cause of death worldwide and does not have a pharmacological treatment for cure or prevention^{1,2}. AD progression can be considered as a continuum from CN through EMCI and LMCI, and to AD, characterized by the loss of memory and cognitive dysfunction. In more detail, it has been shown that the transition probabilities from MCI to more severe states of AD at age 65 is 14% higher than the transition from CN, and this likelihood is increasing by age³. Moreover, the studies show that these disorders are associated with dysfunction in the whole brain neural connectivity rather than a local brain region⁴⁻⁶. Therefore, a non-invasive and computational method for modeling the connectivity across the whole brain can help to understand the alterations in the brain network architecture corresponding to the disease progression and provide an opportunity for early diagnosis and understanding of the disease process. In this regard, the use of graph-theoretical methods and complex network theory for modeling the brain as an interconnected network of brain regions have been a focus of interest in recent years^{7,8}. In most of the studies, the general framework for developing the brain networks include the selection of spatial and temporal scale and resolution of the study data⁹⁻¹³, the appropriate atlases that divide the brain into distinct regions¹⁴, the type of connection among regions (anatomical, functional, or effective connectivity)^{15,16}, and finally the methods of estimating these connectivities¹⁷⁻¹⁹.

Resting-state functional magnetic resonance imaging (rs-fMRI), which measures the neural activity in the resting state based on the blood-oxygen-level-dependent (BOLD) contrast, has been widely used to estimate the functional connectivity network of the brain^{20,21}. Studies indicate the emergence of several complex network phenomena such as assortativity^{22,23}, rich-club^{24,25}, clustering^{26,27}, and small-world^{28,29} in these networks. The modularity and the importance of hub regions have also been discussed in several studies³⁰⁻³². Further, considering the sensitivity of these networks to brain disorders³³⁻³⁵, many studies have aimed to develop computational methods for diagnosing and understanding of the disease process³⁶⁻³⁸. Specifically, in the case of AD and its early stages, many studies reported the disturbance of the functional network architecture, indicating the

¹Biomathematics Laboratory, Department of Applied Mathematics, School of Mathematical Science, Tarbiat Modares University, Tehran, Iran. ²Applied Systems Biology, Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute, Jena, Germany. ³Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. *A list of authors and their affiliations appears at the end of the paper. ✉email: y.jamali@modares.ac.ir

a					b				
CN	1.000	0.689	0.603	0.441	CN	0.639±0.032	0.619±0.023	0.549±0.039	0.429±0.031
EMCI	0.689	1.000	0.622	0.465	EMCI	0.627±0.02	0.624±0.019	0.563±0.039	0.443±0.034
LMCI	0.603	0.622	1.000	0.561	LMCI	0.547±0.041	0.559±0.039	0.548±0.023	0.498±0.029
AD	0.441	0.465	0.561	1.000	AD	0.432±0.034	0.446±0.037	0.502±0.032	0.514±0.024
	CN	EMCI	LMCI	AD		CN	EMCI	LMCI	AD

Figure 1. The similarity between study groups follows a trend proportional to the trend of disease progression. (a) The Jaccard similarity coefficient between the four main group networks. (b) For each study group, the 23 subjects of each group were randomly divided into two subgroups of 11 and 12 networks. Then, the mean networks of these 12 and 11 subjects were constructed, and the Jaccard similarity coefficient between these two mean networks was computed. This process was repeated 100 times resulting in 100 Jaccard similarity coefficient matrices. This panel shows the element-wise mean and SD of these matrices.

disappearance of clustering³⁹ and rich-club⁴⁰ phenomena, alterations to the small-world phenomena^{41,42}, decrease in the functional connectivity link weights^{43,44}, and the changes in the spatial distribution of the hub regions (high ranked regions) towards the frontal areas of the brain^{43,45–47}. However, to the best of our knowledge, none of the studies have done a comprehensive comparative assessment of the functional brain network of patients with AD and its early stages that include all of those subjects mentioned above.

The human brain has an intrinsic multi-scale architecture⁴⁸, which is emerged in different aspects of the data: spatial, temporal, and topological aspects¹³. In this study, the alterations in the human brain functional connectivity network corresponded to the progression of the disease from CN through EMCI and LMCI, and to AD were assessed using multi-scale topological analysis. For each study group, a functional connectivity network of 360 brain regions was computed. The results of different analyses that have been done on these networks are divided into three topological scales: analyses at the scale of the whole network (global), analyses at the single vertex scale (local), and analyses that are in between local and global scales (mesoscale)¹³.

The core question throughout this paper is whether these alterations are following a trend proportional to the disease progression in the continuum from CN to AD. The presence of such trends is perceptible in most of the results in this study. However, in some of them, the trends are not entirely proportional to the disease progression and behave differently in the early stages of the AD spectrum. Further, the analysis showed that the functional brain network tends to shift toward a more randomized architecture by the disease progression. Also, it has been observed that the frontoparietal, somatomotor, and default mode modules are affected more than other modules introduced in the next section.

Results

The results of this study are mainly obtained from the comparative analysis of 4 group networks, each representing a study group's functional connectivity network. In order to construct these networks, the fMRI and T1-weighted (T1w) images of 92 subjects (23 subjects for each study group) were passed through a processing pipeline that includes the preprocessing using *fMRIPrep* 20.0.0 (^{49,50}, RRID:SCR_016216), extracting 36 nuisance regressors, parcellating the brain surface area into 360 regions, constructing connectivity network among these regions with Pearson correlation coefficient (PCC), computing the mean of the networks that belong to subjects within each study group, and finally, thresholding these four mean networks. The overall processing pipeline can be found in Supplementary Fig. S1. We used an alpha level of .05 for all statistical tests presented in this study.

Global network analysis. Significant differences were revealed at the global level analysis. The Jaccard similarity coefficient is a measure for evaluating the correlation and the similarity among two vectors. This measure which is between 0 and 1, quantifies the similarity among each pair of vectors so that the higher outputs indicate the higher similarity among the elements of these vectors. Computing this measure among vectorized adjacency matrices (a matrix that use to represent a network, where the value of the element (i, j) of this matrix equals the weight of the link between the vertices i and j) corresponded to the 4 group networks were showed that the similarity between the CN network and disease networks were decreased by the progression of the disease (Fig. 1a). However, the existence of similarity between the brain networks of the subjects belonging to the same study group was still unclear. To obtain a more reliable comparison that takes into account these similarities, the samples of each study group were randomly divided into two subgroups of 12 and 11 samples. Similar to the process explained in the “Methods and materials” section for computing the mean network of each study group based on its 23 samples, two different mean networks were generated for each study group based on these two subgroups of samples. Then, the Jaccard similarity coefficient among the 11-samples mean networks and the 12-samples mean networks were computed. This process was repeated 100 times, resulting in 100 similarity matrices. Then, the element-wise mean and standard deviation (SD) over these matrices were computed, and the results showed the existence of almost similar trends (Fig. 1b). Further, this similarity has also been evaluated based on the PCC method and resulted in almost similar trends, which are shown in Supplementary Fig. S2 online.

Study group	CN	EMCI	LMCI	AD	<i>p</i>	<i>F</i>
The average strength of the links						
Total strength	9.35 ± 5.4	7.84 ± 4.9	7.77 ± 4.5	7.56 ± 3.8	< 0.001	8.76
Long links	0.0068 ± 0.0494	0.0050 ± 0.0443	0.0031 ± 0.0339	0.0029 ± 0.0323	< 0.001	60.76
Short links	0.0500 ± 0.1360	0.0519 ± 0.1488	0.0539 ± 0.1477	0.0541 ± 0.1506	< 0.001	46.19
Inter-module links	0.0022 ± 0.1031	0.0059 ± 0.0876	0.0092 ± 0.0861	0.0108 ± 0.1018	< 0.001	146.3
Intra-module links	0.1695 ± 0.1478	0.1493 ± 0.1274	0.1309 ± 0.1178	0.1218 ± 0.1314	< 0.001	28.13
Pairwise comparison	CN-AD	EMCI-AD	LMCI-AD	CN-EMCI	CN-LMCI	EMCI-LMCI
The pairwise t-test comparison						
Total strength	< 0.001	0.287	0.002	0.001	0.234	0.038
Long links	< 0.001	< 0.001	0.001	0.061	< 0.001	< 0.001
Short links	< 0.001	0.911	< 0.001	< 0.001	< 0.001	< 0.001
Inter-module links	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	0.054
Intra-module links	0.190	< 0.001	0.200	< 0.001	0.010	< 0.001

Table 1. General information about the distribution of the links of the study networks. The top table shows the average strength of the links, which are grouped into long or short links and inter-module or intra-module links. The significance of the pairwise differences is assessed using the t-test and is shown in the bottom table.

The mean and SD of vertex strength (the total weight of the vertex connections) also had a decreasing trend. Furthermore, the links were classified into short and long links based on their euclidean length (the short (long) links were defined as the links that the euclidean distance between its vertices is smaller (larger) than the average distance among all vertices.). For each group network, the average weight of the long links and the average weight of the short links was computed. As shown in Table 1, there was a decreasing trend of the long link weights and an increasing trend of the short link weights proportional to the progression of the disease. In general, there was a significant difference among nodal values of group networks shown in Table 1 ($p < 0.001$), indicating that the total strength and the strength of the long links and the intra-module links are decreasing while the strength of the short links, and the inter-module links are increasing by the disease progression.

There was also an inverse relationship between the local and global efficiency, which are measures for the efficiency of information exchange over the networks. The global efficiency measures the information exchange over the whole network, whereas the local efficiency measures the fault-tolerant of the network by quantifying the information exchange between the neighbors of each vertex when that vertex is removed⁵¹. While local efficiency in the CN group was higher than in other groups, global efficiency in the CN group was lower than LMCI and AD groups (Fig. 2d).

The small-world (six degrees of separation) phenomenon describes that it is possible to reach any network vertex from other vertices by passing through a small chain of connected vertices. It has been shown that in small-world networks, the average shortest path length ($\langle l \rangle$) grows logarithmically with the network size. This phenomenon can be evaluated by measuring $\langle l \rangle$ and the growth rate of the average number of vertices within a distance less than or equal to l from any given vertex ($M(l)$). It has been shown that in small-world networks, $M(l)$ is increasing faster than the exponential growth⁵². The $M(l)$ function plotted in Fig. 2a and the values of $\langle l \rangle$, shown in Fig. 2b, both suggest that the group networks have the small-world property. However, these figures indicate that, similar to the global efficiency shown in Fig. 2d; the changing patterns are not quite proportional to the disease progression. Specifically, in almost all of the figures mentioned above, the only study group which is not following the expected trend is the EMCI group. The existence of the small-world phenomenon along with the high value of average clustering coefficient ($\langle C \rangle$), will lead to a more specific emergence property of complex networks called small-worldness. σ which is equals to the division of the normalized $\langle l \rangle$ by the normalized $\langle C \rangle$, is a measure of evaluating this new phenomenon explained in the section “Methods and materials”. Figure 2d indicates that in all networks, $\sigma > 1$, which means that they all have the small-worldness property. This figure also indicates that σ , and consequently the small-worldness, increase by the disease progression with the exception of the EMCI group, which is not following the trend. There was also a significant difference between the nodal clustering coefficient ($p < 0.001$) and the shortest path length ($p < 0.001$) of the group networks, indicating that the networks tend to become less clustered and more small-world by the disease progression.

Mesoscale network analysis. The analysis that had been done in the mesoscale indicates the existence of trends similar to the analyses at the global scale.

Clustering, assortativity, and rich-club. The clustering, assortativity, and rich-club phenomena have been used to describe the higher-level architecture of a complex network. The high value of $\langle C \rangle$ indicates the presence of highly interconnected groups of vertices within the network. This measure which is depicted in the second bar plot of Fig. 2d, shows that the clustering phenomenon is decreasing with the disease progression. The assortativity phenomenon is characterized when neighbor vertices are likely to have similar degrees. In Fig. 2b, the increasing diagram of the average degree of the nearest neighbors for vertices of degree k ($k_{nn}(k)$) indicates the presence of this phenomenon. This figure and the last bar plot in Fig. 2d showing the PCC between the degrees




Figure 2. The emergence of the small-worldness, assortativity, and rich-club phenomenon in the group networks. (a) $M(l)$ plot showing the average number of vertices within a distance less than or equal to l from any given vertex is almost increased by the disease progression and suggests that the group networks have the small-world property that is almost stronger in the disease networks. Two graphs on the right-hand side are toy examples to provide intuition on the relationship between the small-world property and randomness, demonstrating the increase in the randomness of network connections (from bottom to top), which leads to the increase in the emergence of the small-world property. The bottom network is more regular, whereas the top one is more random. As a result, the average shortest path length is shorter in the random network (top) than the regular one (bottom), causing the regular network to be less small-world. (b) $K_{nn}(k)$ plot showing the average degree of the nearest neighbors, for vertices of degree k , is almost decreased by the disease progression and suggests that the group networks have assortative architecture, and this assortative matching follows a decreasing trend proportional to the disease progression. Two graphs on the right-hand side are toy examples of assortative (top) and disassortative (bottom) networks to provide intuition on the assortative patterns. As it is obvious, in the bottom network, high degree vertices are more connected with low degree vertices (disassortative pattern), whereas, in the top network, its vertices tend to make connections with other vertices that have similar degrees (assortative pattern). (c) $\rho(k)$ plot showing the amount of inter-connectivity among vertices of degree higher than k is almost decreased by the disease progression and suggests that the rich-club phenomenon is disappearing by the disease progression. Two graphs on the right-hand side are toy examples of networks with (top) and without (bottom) rich-club. In the bottom network, there is no significant inter-connectivity among high-degree vertices (rich vertices). However, in the top network, which is an example of a rich-club network, high-degree vertices are completely inter-connected. (d) The bar plots showing $\langle C \rangle$, $\langle l \rangle$, global efficiency, local efficiency, σ (normalized $\langle C \rangle$ / normalized $\langle l \rangle$), and r (PCC between the degrees of all vertices at either ends of a link).

of all vertices at either ends of a link (r) in each group network, also indicate that the assortativity is disappearing by the disease progression. The rich-club phenomenon is characterized when large degree vertices are more interconnected with each other than with the smaller degree vertices. The diagram in Fig. 2c plotting the fraction of links connecting vertices with degree higher than k out of the maximum number of links that these vertices can possibly share ($\rho(k)$), indicates the presence of the rich-club phenomenon, which is disappearing by the disease progression.

Modular analysis. The 360 brain regions were classified into seven modules based on a well-known parcellation provided by Yeo et al.⁵³ (Fig. 3a). Then, the topological architecture of intra-module and inter-module connection networks was analyzed. First, by reorganizing the position of vertices in each group network’s adjacency matrix based on this classification, a substantial structure that was disappearing with the progression of the disease was observed (see Supplementary Fig. S3 online). Then, the average weight of the intra-module links and the average weight of the inter-module links were computed for each group network. As it is shown in Table 1, there was an increasing trend of the inter-module link weights and an increasing trend of the intra-module link weights proportional to the progression of the disease, and there was a significant difference among nodal values




Figure 3. The overall gradually changing patterns of highly-weighted links are following a trend proportional to the disease progression. **(a)** The spatial distribution of the 7-module parcellation. **(b)** The top 1 percent highly-weighted links of each group network. Vertex color represents the module the vertex belongs to, and the vertex size is proportional to the vertex strength. It shows that there is a trend towards the increase in the number of default mode links as well as the decrease in the inter-hemisphere links in dorsal attention. Visualizations were created using *ggseg* 1.6.1 R package⁵⁴ **(a)** and *Nilearn* 0.6.2 (<https://nilearn.github.io>) **(b)**.

of group networks ($p < 0.001$). Then, similar to the “Global network analysis” section where the PCC between adjacency matrices of the group networks was measured, for each module, the PCC was computed among the adjacency matrices of the modular sub-network of each group network. The results showed that these modules are sensitive to the disease progression (see Supplementary Fig. S4 online).

Local network analysis. Several approaches have been attempted to attain a general conclusion about the distribution of the regions and links that are most sensitive to the disease progression at the finest topological scale.

In order to attain the most sensitive vertices, the spatial distribution of the hub vertices (vertices whose strength is higher than $mean + 2 \times SD$ of all vertices) and the diseased-related activated and deactivated vertices were calculated (Fig. 4b,c). Further, the frequency distribution of these vertices across the 7-module parcellation introduced in the “Modular analysis” section is shown in Fig. 4a.

In order to attain the most sensitive links, for each disease stage two networks including the significantly activated and deactivated links in the diseased network with respect to the CN network were constructed. As it is obvious in Fig. 5a–d, These networks show a similar connectivity pattern among the seven modules, which is becoming more and more apparent with disease progression. Further, we have statistically evaluated the significance of the patterns in the disease-related activated or deactivated networks, presented in Fig. 5. In order to do that, we first categorized the links based on whether they were inter-module or intra-module. Then we used the ANOVA test to check if there is a significant difference between the strength of the links belonging to different inter-module (intra-module) categories. The results showed that these differences were significant with $p < 0.001$ for all disease groups.

Also, the overall gradually changing pattern of the top 1 percent highly-weighted links of the group networks is depicted in Fig. 3b. It shows a changing pattern toward increasing the number of default mode links and decreasing the inter-hemisphere links in the dorsal attention module. Further, the significance of these trends were statistically evaluated using the Chi-squared test with $p < 0.001$ for default mode links and $p = .005$ for intra-hemisphere links in dorsal attention. In order to do that, we computed the number of inter-module (intra-module) links that appeared among the top 1 percent strongest links of each group network and also the number of inter-module (intra-module) links that did not appear among them. Then we used the chi-squared test to see whether these numbers were significantly different across study groups. We further categorized the links based on both their module and the hemisphere they belong to and repeated the similar chi-squared test. In Supplementary




Figure 4. The distribution of hubs, activated areas, and deactivated areas shows that anterior regions are more engaged in the diseased groups. **(a)** The frequency distribution across the 7-module parcellation. The left and right sides of each sub-plot denoted by a vertical black line represent the distribution across modules limited to the left and right hemispheres, respectively **(b)** The spatial distribution of the hub regions. The vertex size is proportional to the vertex strength. **(c)** The spatial distribution of vertices that are activated (denoted by \blacktriangle) and deactivated (denoted by \blacktriangledown) in the diseases. A vertex was called activated (deactivated) with respect to disease if the subtraction of its strength in the disease network from the CN network was significantly larger (smaller) than the similar value for other vertices. The vertex size is proportional to the value of this subtraction. Visualizations in **(b)** and **(c)** were created using *Nilearn* package.

information, Fig. S5, we have provided detailed axial images indicating the brain areas in which the trends have appeared. Also, a larger figure similar to Fig. 3b has been added to the Supplementary information (Fig. S6).




Figure 5. The alterations in the brain functional network induced by the disease progression. For each disease stage, the connectogram of the links with significantly higher (activated) or lower (deactivated) weights compared to the CN group is depicted in the top four panels: **(a)** connectogram of intra-module links activated in each disease stage compared to the CN group, **(b)** Connectogram of inter-module links activated in each disease stage compared to the CN group, **(c)** connectogram of intra-module links deactivated in each disease stage compared to the CN group, and **(d)** Connectogram of inter-module links deactivated in each disease stage compared to the CN group. For each disease group, the activated (deactivated) links compared to the CN group are defined as the significantly larger (smaller) elements of the matrix resulting from the subtraction of the disease network from the CN network. Diagrams are plotted based on the *Hierarchical Edge Bundling* algorithm⁵⁵ using *ObservableHQ* platform (<https://observablehq.com>). This algorithm allows bundling the intra-module links to get a more elegant presentation. Panel **(e)** indicates the activation or deactivation in the vertices' strength by showing the top-view spatial distribution of the activated or deactivated vertices similar to Fig. 4c.

Discussion

The main goal of this study was to investigate the alterations of the brain functional network topology in patients with AD, LMCI, and EMCI compared to the CN patients from a multi-scale topological perspective. This study attempted to find quantitative network measures that are proportional to the trend of brain deterioration from CN patients through AD in order to suggest network-based biomarkers and also help to understand the disease process. There are three general findings in this study. First, the functional brain network constructed in this study is sensitive to the progression of AD. Second, the functional brain network of the diseased groups tends to shift towards a more randomized and integrated architecture. Third, the present study suggests that the alterations in the network architecture may not be entirely proportional to the disease progression. In this regard, the functional brain network architecture may go through a nonlinear process and behave differently in earlier stages in the course of the disease progression.

Several study results suggested that the networks of the disease groups have larger global efficiency. These results include the increase in the global efficiency, the small-world property, and the proportion of inter-module to intra-module link weights. There are also several results suggesting the smaller local efficiency. These results include the decrease in the local efficiency, $\langle C \rangle$, and the proportion of intra-module to inter-module link weights. This inverse relationship which is reported by previous brain studies^{56,57} can be explained by considering the increase of global efficiency as a compensatory mechanism for the decrease in the local efficiency. This will lead to the efficiency in information spreading across the whole brain but the loss of efficacy in information spreading in the finer scales of vertices and their neighbors. Considering the sparse nature of the brain networks, the increase in the global and decrease in the local efficiency indicate that the disease networks have a more random organization.

The analysis at the mesoscale revealed the alteration in the brain network organization in a way that causes the disappearance of the assortative mixing and the rich-club phenomenon. $\rho(k)$ is declining by the disease progression, and in the case of the AD network, it is around 1 in almost everywhere, which means that the brain network tends to behave more similarly to random networks. This significant rich-club reorganization magnifies the importance of analyzing the alterations of the hub regions. The diseased networks' hubs are more distributed over the modules, and it is consistent with the claim that the diseased networks are more randomized and integrated. Furthermore, the diseased groups have significantly more hubs located in anterior regions as compared to the CN group. In more detail, the analysis of activated and deactivated areas shows that the default mode, frontoparietal, and somatomotor modules have been significantly affected by the disease. As suggested by Sha et al.⁵⁸, this observation can find its explanation in the functionality of these modules: frontoparietal is responsible for cognitive control, the default mode network is involved in internal emotional processing, self-referential directed thought, and memory function⁵⁸, and somatomotor is responsible for motor skill learning and sensory perception. Furthermore, as it is also reported by other studies^{59,60}, in addition to these modules, the dorsal and ventral attention, which are respectively involved in the top-down and bottom-up attention process, are also significantly involved in the networks of the disease-related alterations.

As described in the “Network efficiency” subsection, the quality of being random or regular in complex networks is closely related to global and local efficiency, small-worldness, average clustering, and average shortest path length. Further, in the AD network, the disappearance of rich-club organization, the location hub regions more uniformly distributed over the seven modules, and the decrease in the values of Fig. 1b indicates the increase in the AD network randomness. In general, the present analysis results suggest that the brain network tends to shift towards a random structure by the disease progression. There are also several measures for assessing the integration in brain networks, including the decrease in average clustering and the intra-module link weights, as well as the increase in average shortest path length and the inter-module link weights.

Despite several advantages in this study, some limitations should be addressed. First, due to the ill-posed nature of constructing functional network problems and due to the lack of ground truth in any of the main steps for generating functional networks out of neuroimaging data, many different strategies can be used for this purpose⁶¹. Previous studies have shown that depend on the type of analysis, different strategies can lead to different results^{14,62}. Therefore, a comparative analysis of different strategies would help choose appropriate strategies depending on the different scales of topological network analysis and investigate whether a single strategy would be appropriate for all scales. Second, because of the same reasons mentioned in the first limitation, it can be difficult to distinguish which strategy leads to the results that present a more valid biological interpretation⁶¹. In the case of using these results for developing machine learning models, this lack of interpretability is acceptable, but interpreting these results in order to understand the disease process and the underlying mechanisms that lead to the disease, should be done more carefully.

In conclusion, the analyses offered in this paper can help to gain an understanding of the topological changes in the functional brain network architecture. Most previous studies for analyzing the AD spectrum, focused on one topological scale. Using a multi-scale topological approach, this paper extensively demonstrated the pathological changes in the AD process. The issues mentioned in the limitations are the subjects of future works. A comparative assessment of different functional networks constructed based on widely used strategies will help to find strategies with higher sensitivity to the AD spectrum.

Methods and materials

Demographic and clinical information. Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). Hundreds of patients took part in the ADNI project, which launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure

Group	CN	EMCI	LMCI	AD	<i>p</i>	<i>F</i>
Demographic and clinical information						
Number	23	23	23	23	-	-
Male, female	8,15	12,11	10,13	11,12	.673	-
Age (mean ± SD)	75.82 ± 9.44	75.29 ± 6.36	72.26 ± 7.05	77.75 ± 3.75	.396	1.00
MMSE (mean ± SD)	28.96 ± 1.17	28.32 ± 1.89	25.87 ± 3.86	20.32 ± 4.26	< 0.001	33.16
GDSCALE (mean ± SD)	1.04 ± 1.41	1.80 ± 1.85	1.94 ± 2.29	1.37 ± 1.32	.588	0.65
Global CDR (mean ± SD)	0.40 ± 0.13	0.39 ± 0.24	0.49 ± 0.25	0.96 ± 0.40	< 0.001	46.41
FAQ (mean ± SD)	0.25 ± 1.22	2.77 ± 4.22	5.06 ± 6.68	18.26 ± 7.87	< 0.001	46.61
NPI-Q (mean ± SD)	0.67 ± 1.54	2.47 ± 2.52	2.08 ± 1.98	4.85 ± 3.78	.002	5.41
Pairwise comparison	CN-AD	EMCI-AD	LMCI-AD	CN-EMCI	CN-LMCI	EMCI-LMCI
The pairwise t-test comparison						
Age	0.932	0.539	0.202	0.878	0.512	0.919
MMSE	< 0.001	< 0.001	< 0.001	0.880	0.047	0.233
GDSCALE	0.817	0.961	0.982	0.523	0.596	0.999
Global CDR	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	0.515
FAQ	< 0.001	< 0.001	< 0.001	0.582	0.060	0.581
NPI-Q	0.429	0.633	< 0.001	0.987	0.067	0.029

Table 2. Demographic and clinical information of the studied groups is shown in the top table. The pairwise t-test comparisons of the clinical information are presented in the bottom table.

the progression of MCI and early AD. All statements were performed in accordance with relevant guidelines and regulations. Table 2 shows the demographic and clinical information of the 92 study subjects, which are selected from a sample of 96 subjects from the ADNI2 dataset. After estimating a correlation matrix for each participant, in each disease group, a participant with less similarity among the group participants was excluded. The ANOVA assessment showed that the study groups are aged-matched ($F(3,88)=1.00149$, $p=0.396122$). Also, except for the GDSCALE, other clinical information presented in Table 2, were significantly different across the study groups.

The information provided in Table 2 is obtained from different clinical and psychological tests. The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is the most common test for measuring cognitive impairment used in clinical assessments⁶³. The Geriatric Depression Scale (GDS) is a 30-item yes-or-no questionnaire about the participants' feelings over the past week⁶⁴. The Global Clinical Dementia Rating (Global CDR) is a rating scale for staging patients diagnosed with dementia⁶⁵. The Functional Activities Questionnaire (FAQ) measures instrumental activities of daily living, such as housework and shopping⁶⁶. The Neuropsychiatric Inventory Questionnaire (NPI-Q) measures the presence of Neuropsychiatric Symptoms⁶⁷.

Many studies have recently viewed the AD continuum as a continuous spectrum characterized by biomarkers and neuropathological findings^{68–70}. However, in the case of using functional brain network analysis for studying the progression of AD, subdividing the continuum into distinct categories based on their clinical symptoms has been widely used to represent the AD continuum^{71,72}. It is worth mentioning that a growing number of studies use biomarkers based on the levels of Amyloid-beta and p-tau proteins in cerebrospinal fluid^{73,74}. The criteria that ADNI2 used to classify Alzheimer's disease continuum into four stages (CN, EMCI, LMCI, and AD), is mainly based on MMSE score, Wechsler Memory Scale, and global CDR. More details on the inclusion/exclusion criteria are available on the ADNI2 protocol document (adni.loni.usc.edu/wp-content/themes/freshnews-dev-v2/documents/clinical/ADNI-2_Protocol.pdf). The fMRI and T1w images of 23 samples for each study group were collected from the ADNI database of hundreds of patients. According to the ADNI data acquisition protocol, Siemens (Slice Thickness = 4.0; TE = 13.0; TR = 3400.0) and Philips (Slice Thickness = 3.3; TE = 30.0; TR = 3000.0) scanners with Field Strength=3.0 were used for data acquisition. It is worth mentioning that, a growing number of studies recently subdivided the MCI study cohort on the basis of AD-pathological load^{75,76}. In this study, the main reason for choosing the four stage categorization is the existence of many articles that use the same categorization for analyzing AD via network science^{77–79}, and it provides a better opportunity to compare and validate our results with the other's findings.

Preprocessing. The neuroimaging data was preprocessed using *fMRIprep* 20.0.0, which is based on *Nipype* 1.4.2 (^{80,81}, RRID:SCR_002502).

Anatomical data preprocessing. The T1w image was corrected for intensity non-uniformity (INU) with 'N4BiasFieldCorrection'⁸², distributed with ANTs 2.2.0⁸³, RRID:SCR_004757], and used as T1w-reference throughout the workflow. The T1w-reference was then skull-stripped with a *Nipype* implementation of the 'antsBrainExtraction.sh' workflow (from ANTs), using OASIS30ANTs as target template. Brain tissue segmentation of cerebrospinal fluid (CSF), white-matter (WM) and gray-matter (GM) was performed on the brain-extracted T1w using 'fast' [FSL 5.0.9, RRID:SCR_002823⁸⁴]. Brain surfaces were reconstructed using 'recon-all' [FreeSurfer 6.0.1, RRID:SCR_001847⁸⁵], and the brain mask estimated previously was refined with a custom variation of the method to reconcile ANTs-derived and FreeSurfer-derived segmentations of the cortical gray-matter of

Mindboggle [RRID:SCR_002438⁸⁶]. Volume-based spatial normalization to one standard space (MNI152NLin-2009cAsym) was performed through nonlinear registration with ‘antsRegistration’ (ANTs 2.2.0), using brain-extracted versions of both T1w reference and the T1w template. The following template was selected for spatial normalization: *ICBM 152 Nonlinear Asymmetrical template version 2009c*⁸⁷, RRID:SCR_008796; TemplateFlow ID: MNI152NLin2009cAsym].

Functional data preprocessing. For each of the BOLD runs found per subject (across all tasks and sessions), the following preprocessing was performed. First, a reference volume and its skull-stripped version were generated using a custom methodology of *fMRIPrep*. Susceptibility distortion correction (SDC) was omitted. The BOLD reference was then co-registered to the T1w reference using ‘bbrregister’ (FreeSurfer) which implements boundary-based registration⁸⁸. Co-registration was configured with six degrees of freedom. Head-motion parameters with respect to the BOLD reference (transformation matrices, and six corresponding rotation and translation parameters) are estimated before any spatiotemporal filtering using ‘mcflirt’ [FSL 5.0.9⁸⁹]. The BOLD time-series were resampled onto the following surfaces (FreeSurfer reconstruction nomenclature): *fsaverage5*. The BOLD time-series (including slice-timing correction when applied) were resampled onto their original, native space by applying the transforms to correct for head-motion. These resampled BOLD time-series will be referred to as *preprocessed BOLD in original space*, or just *preprocessed BOLD*. The BOLD time-series were resampled into standard space, generating a *preprocessed BOLD run in MNI152NLin2009cAsym space*. First, a reference volume and its skull-stripped version were generated using a custom methodology of *fMRIPrep*. Several confounding time-series were calculated based on the *preprocessed BOLD*: framewise displacement (FD), DVARS and three region-wise global signals. FD and DVARS are calculated for each functional run, both using their implementations in *Nipype* [following the definitions by⁹⁰]. The three global signals are extracted within the CSF, the WM, and the whole-brain masks. Additionally, a set of physiological regressors were extracted to allow for component-based noise correction [*CompCor*⁹¹]. Principal components are estimated after high-pass filtering the *preprocessed BOLD* time-series (using a discrete cosine filter with 128s cut-off) for the two *CompCor* variants: temporal (tCompCor) and anatomical (aCompCor). tCompCor components are then calculated from the top 5% variable voxels within a mask covering the subcortical regions. This subcortical mask is obtained by heavily eroding the brain mask, which ensures it does not include cortical GM regions. For aCompCor, components are calculated within the intersection of the aforementioned mask and the union of CSF and WM masks calculated in T1w space, after their projection to the native space of each functional run (using the inverse BOLD-to-T1w transformation). Components are also calculated separately within the WM and CSF masks. For each CompCor decomposition, the *k* components with the largest singular values are retained, such that the retained components’ time series are sufficient to explain 50 percent of variance across the nuisance mask (CSF, WM, combined, or temporal). The remaining components are dropped from consideration. The head-motion estimates calculated in the correction step were also placed within the corresponding confounds file. The confound time series derived from head motion estimates and global signals were expanded with the inclusion of temporal derivatives and quadratic terms for each⁹². Frames that exceeded a threshold of 0.5 mm FD or 1.5 standardised DVARS were annotated as motion outliers. All resamplings can be performed with a *single interpolation step* by composing all the pertinent transformations (i.e. head-motion transform matrices, susceptibility distortion correction when available, and co-registrations to anatomical and output spaces). Gridded (volumetric) resamplings were performed using ‘antsApplyTransforms’ (ANTs), interpolation to minimize the smoothing effects of other kernels⁹³. Non-gridded (surface) resamplings were performed using ‘mri_vol2surf’ (FreeSurfer).

Next, confound regression with 36-parameters (including 6 motion parameters of translation and rotation, mean signal in white matter, mean signal in cerebrospinal fluid, and global signal, as well as their derivatives, quadratic terms, and squares of derivatives) were conducted to the data resampled onto FreeSurfer *fsaverage5* surface space⁹².

Network construction. The human connectome project’s multi-modal parcellation, version 1.0 (HCP_MMP 1.0)⁹⁴ were used to parcellate each participant’s data into 360 regions. It has been shown that this parcellation is more robust and sensitive to AD progression than many other widely used parcellations, and it is probably the most detailed cortical in-vivo parcellation available to date^{14,95}. The time series corresponding to each region is then the mean of the time series of voxels within that region. Then, the weighted undirected functional connectivity network was obtained by computing the PCC between time series of all regions. In order to obtain a single network for each study group, the mean network of each group was computed as the element-wise mean of all networks belong to the subjects within that group. Finally, instead of using a constant threshold value to remove weak links in each group, we used a data-driven method to compute a threshold value. This new criterion is inspired by the fact that complex networks have strong global efficiency as well as sparsity. Furthermore, it has been shown that this approach has a good potential for the diagnosis of Alzheimer’s disease. For each network, we searched for a thresholding value that maximizes the global efficiency (*E*) minus the proportion of the strongest weights (*PSW*) (Eqs. 1, 2)⁹⁶.

$$E(t) = \frac{1}{n} \sum_{i \in N} \frac{\sum_{j \in N, j \neq i} (\frac{1}{d_{ij}})}{n-1} \quad (1)$$

$$PSW(t) = \frac{\sum_{i \in W, i \geq t} i}{\sum_{j \in W} j} \quad (2)$$

where N is the set of all vertices, n is the number of vertices, d_{ij} is the shortest path length between vertices i and j , and W is the set of all weights. However, the results of this method were not very different from using the same thresholds for each group, and the resulting thresholds were close to each other (CN: 0.093, EMCI: 0.086, LMCI: 0.101, AD: 0.083).

Network analysis. The study of large-scale complex networks includes a wide range of statistical measures that have been defined for the study of large-scale complex networks as characteristics for network architectures. Most of these measures have specific real-world interpretations. However, some of them have been shown to be more manifested in real-world networks, and more specifically the brain networks, representing their intrinsic complexity^{97,98} (e.g., small-worldness and efficiency), heterogeneity⁹⁹ (e.g., degree distribution, hubs), hierarchical structure^{24,100} (e.g., rich-club, assortativity, clustering, and hubs), integration (e.g., small-world, clustering, local efficiency), and segregation (e.g., average shortest path length, global efficiency)^{32,101}. This study used a collection of most dominant measures that can evaluate these features and also capture different topological scales¹³. Further, these measures have been widely used in studying the AD continuum^{40,47,102}.

Network efficiency. The efficiency of information exchange throughout the networks can be assessed from local and global perspectives^{51,103,104}.

Having a small $\langle l \rangle$ leads to efficient information exchange from the global point of view. Accordingly, several quantitative methods were introduced to assess this efficiency. The global efficiency, which is the inverse sum of the shortest path length among vertices, is one of them⁵¹. The small-world property which is a common emergence phenomenon among many real-world complex network systems, also guarantees high efficiency in the information exchange from the global perspective. This measure that also calls the six degrees of separation, exists if $\langle l \rangle$ scales slower than the logarithmic growth with the size of the network. $M(l)$ is defined as the average number of vertices within a distance less than or equal to l from any given vertex. Then $M(l)$ is expected to grow faster than the exponential growth in the small-world networks⁵².

It has been shown that many real-world complex networks are mostly sparse networks with high $\langle C \rangle$ ¹⁰⁵ that will lead to the efficiency in the local information exchange. This efficiency can also be assessed by measuring the average efficiency of the sub-networks, including each vertex and its neighbors⁵¹. Clearly, this efficiency can not be attained if the network has a completely random organization. However, the sparse nature of these networks, along with the existence of the small-world property, implies that these networks can not be like regular networks, and there should be random rearrangements in the connections of these networks to form hubs and connectivity backbones and leads to faster information exchange and decrease in $\langle l \rangle$ ⁵². Therefore, the emergence of both local and global efficiency, which can be explained by the trade-off between the regular and random organization of the connections¹⁰³, was recognized as a new phenomenon, called the small-worldness¹⁰⁶. A straightforward approach for quantifying this phenomenon is to divide the normalized $\langle l \rangle$ by the normalized $\langle C \rangle$ ($\sigma = \langle l \rangle_{rand} / C_{rand}$). The normalization can be done by dividing the actual value of each measure by the value of the measure for a corresponding Erdős-Rényi random graph. A network is then said to have small-worldness if $\sigma > 1$ ¹⁰⁶.

Assortativity. The assortative property refers to the tendency of vertices to connect to other vertices with similar degree. In this study, this property was measured using two methods. First, the PCC between the degrees of all vertices on either ends of a link was computed as:

$$r = \frac{\sum_e j_e k_e / E - [\sum_e (j_e + k_e) / (2E)]^2}{[\sum_e (j_e^2 + k_e^2) / (2E)] - [\sum_e (j_e + k_e) / (2E)]^2} \quad (3)$$

where j_e and k_e denote the degree of the extremities of link e and E is the total number of links. This quantity lies in the range $-1 \leq r \leq 1$, where -1 refers to disassortative networks and 1 refers to totally assortative networks¹⁰⁷. The second method measures the assortativity by computing the average degree of the nearest neighbors, for vertices of degree k ($k_{nn}(k)$).

$$k_{nn}(k) = \frac{1}{N_k} \sum_{i/k_i=k} k_{nn,i} \quad (4)$$

where N_k is the number of vertices with degree k and $k_{nn,i}$ is the average degree of the nearest neighbors, for the vertex i . If $k_{nn}(k)$ is an increasing function of k , the average degree of the nearest neighbors, for vertices of degree k will increase by k which means that the probability of these vertices being connected with large degree vertices is increasing and this corresponds to an assortative mixing¹⁰⁷.

Rich-club. The rich-club property indicates the tendency of high degree vertices, to be connected to each other and forming clubs. It can be quantitatively measured as:

$$\phi(k) = \frac{2E_{>k}}{N_{>k}(N_{>k} - 1)} \quad (5)$$

where $E_{>k}$ is the number of links among the vertices with degree larger than k , and $N_{>k}$ is the number of vertices with degree larger than k . In order to obtain a more representative measure, the $\phi(k)$ of the network under study was normalized by dividing with the $\phi(k)$ of a random network with the same degree distribution as the

network under study. This function is called $\rho_{ran}(k)$. If $\rho_{ran}(k)$ is an increasing function of k , the sub-networks containing vertices with degree larger than k will be denser as k increases and this implies the presence of a rich-club organization¹⁰⁸.

Sensitive vertices and links. Given a scoring system for vertices, network hubs are defined as the vertices whose score is significantly higher than others ($> \text{mean} + 2 \times \text{SD}$). In this study, we used strength as the scoring system. Additionally, by defining a new score as the subtraction of the score of the network under study (in here the disease networks) from a reference network (in here the CN network), the activated regions in that network with respect to the reference network, is then computed as the vertices that their new score is significantly higher than others, respectively the deactivated regions are the ones that their new score is significantly lower. Further, a scoring system for network links was defined by computing the difference between the adjacency matrix of the disease networks and the CN network. Likewise, for each disease group, the activated (deactivated) links were determined as links whose score is significantly higher (lower) than others.

Statistical analyses. In General, One-Way ANOVA and Chi-squared (χ^2) tests have been performed for continuous or categorical variables, respectively, throughout the results. Additionally, Kruskal-Wallis one-way analysis of variance, which is a nonparametric alternative to the One-Way ANOVA test was used in this analysis (all with $p < 0.05$).

Further, As it is also explained in the “Rich-club” and “Network efficiency” subsections, in order to assess the significance of the rich-club and small-worldness, the $\phi(k)$ and the σ functions were included a standardization part in which these functions were computed for a collection of 1000 randomly generated networks with the same degree distribution as the original networks (based on edge_swap algorithm).

The main approach of this study was to perform complex network analysis on the brain connectivity in each disease stage. Therefore, one goal was to estimate a single brain network for each stage of the disease. To do so, as many other studies suggest^{109–112}, averaging the networks over all participants within each group was the best option for estimating the group networks. Indeed, one concern in this study was whether the group averaged networks could represent the group participants. In this regard, a permutation test was designed that repetitively creates two average networks for each disease group using random permutations and investigates whether these average networks are more similar to each other than the average networks of other diseases (Fig. 1b).

Data availability

The four main group networks are available in Supplementary Materials, and all other intermediate data are available from the corresponding author upon request. Further, the codes for this study are available at <https://github.com/Alirezafathian/fmriprediction>.

Received: 19 April 2021; Accepted: 23 August 2022

Published online: 02 September 2022

References

- 2020 alzheimer's disease facts and figures. *Alzheimer's & Dementia* **16**, 391–460. <https://doi.org/10.1002/alz.12068>. <https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12068>.
- Organization, W. H. *Global Tuberculosis Report 2019*. Global tuberculosis control (World Health Organization, 2019).
- Davis, M. *et al.* Estimating alzheimer's disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. *Curr. Alzheimer Res.* **15**, 777–788 (2018).
- Supekar, K., Menon, V., Rubin, D., Musen, M. & Greicius, M. D. Network analysis of intrinsic functional brain connectivity in alzheimer's disease. *PLoS Comput. Biol.* **4**, e1000100 (2008).
- Zhou, J. *et al.* Divergent network connectivity changes in behavioural variant frontotemporal dementia and alzheimer's disease. *Brain* **133**, 1352–1367 (2010).
- Filippi, M. & Rocca, M. A. Clinical applications of the functional connectome. In *fMRI Techniques and Protocols*, 893–903 (Springer, 2016).
- Bullmore, E. & Sporns, O. Complex brain networks: Graph theoretical analysis of structural and functional systems. *Nat. Rev. Neurosci.* **10**, 186–198 (2009).
- Bassett, D. S. & Sporns, O. Network neuroscience. *Nat. Neurosci.* **20**, 353–364 (2017).
- Betz, R. F. *et al.* Changes in structural and functional connectivity among resting-state networks across the human lifespan. *Neuroimage* **102**, 345–357 (2014).
- Tewarie, P. *et al.* Tracking dynamic brain networks using high temporal resolution meg measures of functional connectivity. *Neuroimage* **200**, 38–50 (2019).
- Peer, M., Ron, Y., Monsa, R. & Arzy, S. Processing of different spatial scales in the human brain. *ELife* **8**, e47492 (2019).
- Moerel, M., Yacoub, E., Gulban, O. F., Lage-Castellanos, A. & De Martino, F. Using high spatial resolution fmri to understand representation in the auditory network. *Prog. Neurobiol.* 101887 (2020).
- Betz, R. F. & Bassett, D. S. Multi-scale brain networks. *Neuroimage* **160**, 73–83 (2017).
- Wu, Z. *et al.* Effects of brain parcellation on the characterization of topological deterioration in alzheimer's disease. *Front. Aging Neurosci.* **11**, 113 (2019).
- Lang, E. W., Tomé, A. M., Keck, I. R., Górriz-Sáez, J. & Puntonet, C. G. Brain connectivity analysis: A short survey. *Computat. Intell. Neurosci.* (2012).
- Rossini, P. *et al.* Methods for analysis of brain connectivity: An ifcn-sponsored review. *Clin. Neurophysiol.* **130**, 1833–1858 (2019).
- Bastos, A. M. & Schoffelen, J.-M. A tutorial review of functional connectivity analysis methods and their interpretational pitfalls. *Front. Syst. Neurosci.* **9**, 175 (2016).
- Sotiropoulos, S. N. & Zalesky, A. Building connectomes using diffusion mri: Why, how and but. *NMR Biomed.* **32**, e3752 (2019).
- Stephan, K. E. & Friston, K. J. Analyzing effective connectivity with functional magnetic resonance imaging. *Wiley Interdiscip. Rev. Cognit. Sci.* **1**, 446–459 (2010).
- Wang, J., Zuo, X. & He, Y. Graph-based network analysis of resting-state functional mri. *Front. Syst. Neurosci.* **4**, 16 (2010).

21. Van Den Heuvel, M. P. & Pol, H. E. H. Exploring the brain network: a review on resting-state fmri functional connectivity. *Eur. Neuropsychopharmacol.* **20**, 519–534 (2010).
22. Duda, J. T., Cook, P. A. & Gee, J. C. Reproducibility of graph metrics of human brain structural networks. *Front. Neuroinform.* **8**, 46 (2014).
23. Betzel, R. F., Bertolero, M. A. & Bassett, D. S. Non-assortative community structure in resting and task-evoked functional brain networks. *bioRxiv* 355016 (2018).
24. Grayson, D. S. *et al.* Structural and functional rich club organization of the brain in children and adults. *PLoS ONE* **9**, e88297 (2014).
25. Kim, D.-J. & Min, B.-K. Rich-club in the brain's macrostructure: Insights from graph theoretical analysis. *Comput. Struct. Biotechnol. J.* (2020).
26. Yin, C. *et al.* Network science characteristics of brain-derived neuronal cultures deciphered from quantitative phase imaging data. *Sci. Rep.* **10**, 1–13 (2020).
27. Xiang, J. *et al.* Graph-based network analysis of resting-state fmri: test-retest reliability of binarized and weighted networks. *Brain Imaging Behav.* **14**, 1361–1372 (2020).
28. van den Heuvel, M. P., Stam, C. J., Boersma, M. & Pol, H. H. Small-world and scale-free organization of voxel-based resting-state functional connectivity in the human brain. *Neuroimage* **43**, 528–539 (2008).
29. Bassett, D. S. & Bullmore, E. T. Small-world brain networks revisited. *Neuroscientist* **23**, 499–516 (2017).
30. Oldham, S. & Fornito, A. The development of brain network hubs. *Dev. Cogn. Neurosci.* **36**, 100607 (2019).
31. van den Heuvel, M. P. & Sporns, O. Network hubs in the human brain. *Trends Cogn. Sci.* **17**, 683–696 (2013).
32. Bertolero, M. A., Yeo, B. T. & D'Esposito, M. The modular and integrative functional architecture of the human brain. *Proc. Natl. Acad. Sci.* **112**, E6798–E6807 (2015).
33. Liu, J. *et al.* Complex brain network analysis and its applications to brain disorders: a survey. *Complexity* **2017** (2017).
34. Deco, G. & Kringelbach, M. L. Great expectations: using whole-brain computational connectomics for understanding neuropsychiatric disorders. *Neuron* **84**, 892–905 (2014).
35. Fornito, A. & Bullmore, E. T. Connectomics: a new paradigm for understanding brain disease. *Eur. Neuropsychopharmacol.* **25**, 733–748 (2015).
36. Højati, S. H. *et al.* Predicting conversion from mci to ad using resting-state fmri, graph theoretical approach and svm. *J. Neurosci. Methods* **282**, 69–80 (2017).
37. Castellanos, F. X., Di Martino, A., Craddock, R. C., Mehta, A. D. & Milham, M. P. Clinical applications of the functional connectome. *Neuroimage* **80**, 527–540 (2013).
38. Fornito, A., Zalesky, A. & Breakspear, M. The connectomics of brain disorders. *Nat. Rev. Neurosci.* **16**, 159–172 (2015).
39. He, Y., Chen, Z., Gong, G. & Evans, A. Neuronal networks in alzheimer's disease. *Neuroscientist* **15**, 333–350 (2009).
40. Xue, C. *et al.* Disrupted patterns of rich-club and diverse-club organizations in subjective cognitive decline and amnesic mild cognitive impairment. *Front. Neurosci.* **14** (2020).
41. Sanz-Arigita, E. J. *et al.* Loss of 'small-world' networks in alzheimer's disease: graph analysis of fmri resting-state functional connectivity. *PLoS ONE* **5**, e13788 (2010).
42. Zhao, X. *et al.* Disrupted small-world brain networks in moderate alzheimer's disease: a resting-state fmri study. *PLoS ONE* **7**, e33540 (2012).
43. Dai, Z. *et al.* Identifying and mapping connectivity patterns of brain network hubs in alzheimer's disease. *Cereb. Cortex* **25**, 3723–3742 (2015).
44. Engels, M. M. *et al.* Declining functional connectivity and changing hub locations in alzheimer's disease: an eeg study. *BMC Neurol.* **15**, 1–8 (2015).
45. Pereira, J. B. *et al.* Amyloid network topology characterizes the progression of alzheimer's disease during the prodementia stages. *Cereb. Cortex* **28**, 340–349 (2018).
46. Buckner, R. L. *et al.* Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to alzheimer's disease. *J. Neurosci.* **29**, 1860–1873 (2009).
47. Sui, X. *et al.* Functional connectivity hubs could serve as a potential biomarker in alzheimer's disease: a reproducible study. *Curr. Alzheimer Res.* **12**, 974–983 (2015).
48. Bassett, D. S. & Siebenhühner, F. Multiscale network organization in the human brain. *Multiscale analysis and nonlinear dynamics* 179–204 (2013).
49. Esteban, O. *et al.* fMRIPrep: a robust preprocessing pipeline for functional MRI. *Nat. Methods* <https://doi.org/10.1038/s41592-018-0235-4> (2018).
50. Esteban, O. *et al.* fmriprep. *Software* <https://doi.org/10.5281/zenodo.852659> (2018).
51. Latora, V. & Marchiori, M. Efficient behavior of small-world networks. *Phys. Rev. Lett.* **87**, 198701 (2001).
52. Barrat, A., Barthelemy, M. & Vespignani, A. *Dynamical processes on complex networks* (Cambridge university press, 2008).
53. Yeo, B. T. *et al.* The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J. Neurophysiol.* (2011).
54. Mowinckel, A. M. & Vidal-Piñeiro, D. Visualization of brain statistics with r packages ggseg and ggseg3d. *Adv. Methods Pract. Psychol. Sci.* **3**, 466–483 (2020).
55. Holten, D. Hierarchical edge bundles: Visualization of adjacency relations in hierarchical data. *IEEE Trans. Visual Comput. Graphics* **12**, 741–748 (2006).
56. Stanley, M. L. *et al.* Changes in brain network efficiency and working memory performance in aging. *PLoS ONE* **10**, e0123950 (2015).
57. Ma, X. *et al.* Enhanced network efficiency of functional brain networks in primary insomnia patients. *Front. Psych.* **9**, 46 (2018).
58. Sha, Z. *et al.* Meta-connectomic analysis reveals commonly disrupted functional architectures in network modules and connectors across brain disorders. *Cereb. Cortex* **28**, 4179–4194 (2018).
59. Qian, S., Zhang, Z., Li, B. & Sun, G. Functional-structural degeneration in dorsal and ventral attention systems for alzheimer's disease, amnesic mild cognitive impairment. *Brain Imaging Behav.* **9**, 790–800 (2015).
60. Zhang, Z. *et al.* Functional degeneration in dorsal and ventral attention systems in amnesic mild cognitive impairment and alzheimer's disease: an fmri study. *Neurosci. Lett.* **585**, 160–165 (2015).
61. Bijsterbosch, J. *et al.* Challenges and future directions for representations of functional brain organization. *Nat. Neurosci.* **23**, 1484–1495 (2020).
62. Ciric, R. *et al.* Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. *NeuroImage* **154**, 174–187. <https://doi.org/10.1016/j.neuroimage.2017.03.020> (2017). Cleaning up the fMRI time series: Mitigating noise with advanced acquisition and correction strategies.
63. Arevalo-Rodriguez, I. *et al.* Mini-mental state examination (mmse) for the detection of alzheimer's disease and other dementias in people with mild cognitive impairment (mci). *Cochrane Database Syst. Rev.* (2015).
64. Greenberg, S. A. The geriatric depression scale (gds). *Best Pract. Nurs. Care Older Adults* **4**, 1–2 (2012).
65. Mendez, M. *The Mental Status Examination Handbook* (Elsevier, 2021).
66. Mayo, A. M. Use of the functional activities questionnaire in older adults with dementia. *Hartford Inst. Geriatr. Nurs.* **13**, 2 (2016).

67. Musa, G. *et al.* Utility of the neuropsychiatric inventory questionnaire (npi-q) in the assessment of a sample of patients with alzheimer's disease in chile. *Dement. Neuropsychol.* **11**, 129–136 (2017).
68. Khoury, R. & Ghossoub, E. Diagnostic biomarkers of alzheimer's disease: A state-of-the-art review. *Biomark. Neuropsychiatry* **1**, 100005 (2019).
69. Risacher, S. L. *et al.* Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. *Alzheimer's Dement. Diagn. Assess. Dis. Monit.* **11**, 510–519 (2019).
70. Zetterberg, H. & Schott, J. M. Biomarkers for alzheimer's disease beyond amyloid and tau. *Nat. Med.* **25**, 201–203 (2019).
71. Lama, R. K. & Kwon, G.-R. Diagnosis of alzheimer's disease using brain network. *Front. Neurosci.* **15**, 15 (2021).
72. Li, W. *et al.* Functional evolving patterns of cortical networks in progression of alzheimer's disease: A graph-based resting-state fmri study. *Neural Plast.* **2020** (2020).
73. Sauvée, M. *et al.* Additional use of a β (42)/a β (40) ratio with cerebrospinal fluid biomarkers p-tau and a β (42) increases the level of evidence of alzheimer's disease pathophysiological process in routine practice. *J. Alzheimer's Dis. JAD* **41**, 377–386 (2014).
74. Jack, C. R. *et al.* A/t/n: An unbiased descriptive classification scheme for alzheimer disease biomarkers. *Neurology* **87**, 539–547 (2016).
75. Schindler, S. E. *et al.* Cerebrospinal fluid biomarkers measured by elecsys assays compared to amyloid imaging. *Alzheimer's Dementia* **14**, 1460–1469 (2018).
76. Nation, D. A. *et al.* Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. *Nat. Med.* **25**, 270–276 (2019).
77. Ahmadi, H., Fatemizadeh, E. & Motie-Nasrabadi, A. Identifying brain functional connectivity alterations during different stages of Alzheimer's disease. *Int. J. Neurosci.* 1–13 (2020).
78. Langella, S., Sadiq, M. U., Mucha, P. J., Giovanello, K. S. & Dayan, E. Lower functional hippocampal redundancy in mild cognitive impairment. *Transl. Psychiatry* **11**, 1–12 (2021).
79. Puttaert, D. *et al.* Alterations in resting-state network dynamics along the Alzheimer's disease continuum. *Sci. Rep.* **10**, 1–13 (2020).
80. Gorgolewski, K. *et al.* Nipype: A flexible, lightweight and extensible neuroimaging data processing framework in python. *Front. Neuroinform.* **5**, 13. <https://doi.org/10.3389/fninf.2011.00013> (2011).
81. Gorgolewski, K. J. *et al.* Nipype. *Softw.* <https://doi.org/10.5281/zenodo.596855> (2018).
82. Tustison, N. J. *et al.* N4itk: Improved n3 bias correction. *IEEE Trans. Med. Imaging* **29**, 1310–1320. <https://doi.org/10.1109/TMI.2010.2046908> (2010).
83. Avants, B., Epstein, C., Grossman, M. & Gee, J. Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain. *Med. Image Anal.* **12**, 26–41. <https://doi.org/10.1016/j.media.2007.06.004> (2008).
84. Zhang, Y., Brady, M. & Smith, S. Segmentation of brain MR images through a hidden markov random field model and the expectation-maximization algorithm. *IEEE Trans. Med. Imaging* **20**, 45–57. <https://doi.org/10.1109/42.906424> (2001).
85. Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis: I. segmentation and surface reconstruction. *NeuroImage* **9**, 179–194. <https://doi.org/10.1006/nimg.1998.0395> (1999).
86. Klein, A. *et al.* Mindboggling morphometry of human brains. *PLoS Comput. Biol.* **13**, e1005350. <https://doi.org/10.1371/journal.pcbi.1005350> (2017).
87. Fonov, V., Evans, A., McKinstry, R., Almlí, C. & Collins, D. Unbiased nonlinear average age-appropriate brain templates from birth to adulthood. *NeuroImage* **47**, Supplement 1, S102. [https://doi.org/10.1016/S1053-8119\(09\)70884-5](https://doi.org/10.1016/S1053-8119(09)70884-5) (2009).
88. Greve, D. N. & Fischl, B. Accurate and robust brain image alignment using boundary-based registration. *NeuroImage* **48**, 63–72. <https://doi.org/10.1016/j.neuroimage.2009.06.060> (2009).
89. Jenkinson, M., Bannister, P., Brady, M. & Smith, S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. *NeuroImage* **17**, 825–841. <https://doi.org/10.1006/nimg.2002.1132> (2002).
90. Power, J. D. *et al.* Methods to detect, characterize, and remove motion artifact in resting state fmri. *NeuroImage* **84**, 320–341. <https://doi.org/10.1016/j.neuroimage.2013.08.048> (2014).
91. Behzadi, Y., Restom, K., Liau, J. & Liu, T. T. A component based noise correction method (CompCor) for BOLD and perfusion based fmri. *NeuroImage* **37**, 90–101. <https://doi.org/10.1016/j.neuroimage.2007.04.042> (2007).
92. Satterthwaite, T. D. *et al.* An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. *NeuroImage* **64**, 240–256. <https://doi.org/10.1016/j.neuroimage.2012.08.052> (2013).
93. Lanczos, C. Evaluation of noisy data. *J. Soc. Ind. Appl. Math. Ser. B Numer. Anal.* **1**, 76–85. <https://doi.org/10.1137/0701007> (1964).
94. Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex. *Nature* **536**, 171–178 (2016).
95. Sheng, J. *et al.* A novel joint hcpmp method for automatically classifying alzheimer's and different stage mci patients. *Behav. Brain Res.* **365**, 210–221 (2019).
96. Khazaei, A., Ebrahimzadeh, A. & Babajani-Feremi, A. Application of advanced machine learning methods on resting-state fmri network for identification of mild cognitive impairment and alzheimer's disease. *Brain Imaging Behav.* **10**, 799–817 (2016).
97. Tan, T. L. & Cheong, S. A. Statistical complexity is maximized in a small-world brain. *PLoS ONE* **12**, e0183918 (2017).
98. Misisic, B., Vakorin, V. A., Paus, T. & McIntosh, A. R. Functional embedding predicts the variability of neural activity. *Front. Syst. Neurosci.* **5**, 90 (2011).
99. Gupta, L. *et al.* Spatial heterogeneity analysis of brain activation in fmri. *NeuroImage: Clin.* **5**, 266–276 (2014).
100. Hilgetag, C. C. & Goulas, A. 'hierarchy' in the organization of brain networks. *Philos. Trans. R. Soc. B* **375**, 20190319 (2020).
101. Lord, L.-D., Stevner, A. B., Deco, G. & Kringelbach, M. L. Understanding principles of integration and segregation using whole-brain computational connectomics: implications for neuropsychiatric disorders. *Philos. Trans. R. Soc. A Math. Phys. Eng. Sci.* **375**, 20160283 (2017).
102. Zhou, Y. & Lui, Y. W. Small-world properties in mild cognitive impairment and early alzheimer's disease: A cortical thickness mri study. *Int. Scholar. Res. Not.* **2013** (2013).
103. Liao, X., Vasilakos, A. V. & He, Y. Small-world human brain networks: Perspectives and challenges. *Neurosci. Biobehav. Rev.* **77**, 286–300 (2017).
104. Kawai, Y., Park, J. & Asada, M. A small-world topology enhances the echo state property and signal propagation in reservoir computing. *Neural Netw.* **112**, 15–23 (2019).
105. Demaine, E. D. *et al.* Structural sparsity of complex networks: Bounded expansion in random models and real-world graphs. *J. Comput. Syst. Sci.* **105**, 199–241 (2019).
106. Humphries, M. D. & Gurney, K. Network 'small-world-ness': a quantitative method for determining canonical network equivalence. *PLoS ONE* **3**, e0002051 (2008).
107. Newman, M. E. Assortative mixing in networks. *Phys. Rev. Lett.* **89**, 208701 (2002).
108. Colizza, V., Flammini, A., Serrano, M. A. & Vespignani, A. Detecting rich-club ordering in complex networks. *Nat. Phys.* **2**, 110–115 (2006).
109. Geerligs, L., Renken, R. J., Saliassi, E., Maurits, N. M. & Lorist, M. M. A brain-wide study of age-related changes in functional connectivity. *Cereb. Cortex* **25**, 1987–1999 (2015).

110. Yao, R. *et al.* Dynamic changes of brain networks during working memory tasks in schizophrenia. *Neuroscience* **453**, 187–205 (2021).
111. Weller, A. *et al.* Finding new communities: A principle of neuronal network reorganization in alzheimer's disease. *Brain Connect.* **11**, 225–238 (2021).
112. Vatansever, D. *et al.* Reorganisation of brain hubs across altered states of consciousness. *Sci. Rep.* **10**, 1–11 (2020).

Acknowledgements

This work has been supported in part by a grant from the Cognitive Sciences and Technologies Council with grant No. 8226. In addition, the second author is indebted to the Research Core: “Bio-Mathematics with computational approach” of Tarbiat Modares University, with Grant No IG-39706. We would like to express our great appreciation to Dr. Kazemi for her valuable and constructive suggestions during the revised manuscript. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and provided data but did not participate in analysis or writing of this report.

Author contributions

A.F.: conceptualization, data curation, formal analysis, investigation, methodology, software, validation, visualization, writing—original draft, writing—review and editing; Y.J.: supervision, conceptualization, formal analysis, investigation, methodology, project administration, resources, software, validation, review and editing; M.R.R.: validation, review and editing.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-18987-y>.

Correspondence and requests for materials should be addressed to Y.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

for the Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner⁴, Norbert Schuff^{4,10}, Howard J. Rosen⁴, Bruce L. Miller⁴, Thomas Neylan⁴, Jacqueline Hayes⁴, Shannon Finley⁴, Paul Aisen⁵, Zaven Khachaturian^{5,14}, Ronald G. Thomas⁵, Michael Donohue⁵, Sarah Walter⁵, Devon Gessert⁵, Tamie Sather⁵, Gus Jiminez⁵, Leon Thal⁵, James Brewer⁵, Helen Vanderswag⁵, Adam Fleisher⁵, Melissa Davis⁵, Rosemary

Morrison⁵, Ronald Petersen⁶, Clifford R. Jack⁶, Matthew Bernstein⁶, Bret Borowski⁶, Jef Gunter⁶, Matt Senjem⁶, Prashanthi Vemuri⁶, David Jones⁶, Kejal Kantarci⁶, Chad Ward⁶, Sara S. Mason⁶, Colleen S. Albers⁶, David Knopman⁶, Kris Johnson⁶, William Jagust⁷, Susan Landau⁷, John Q. Trojanowski⁸, Leslie M. Shaw⁸, Virginia Lee⁸, Magdalena Korecka⁸, Michal Figurski⁸, Steven E. Arnold⁸, Jason H. Karlawish⁸, David Wolk⁸, Arthur W. Toga⁹, Karen Crawford⁹, Scott Neu⁹, Lon S. Schneider⁹, Sonia Pawluczyk⁹, Mauricio Beccera⁹, Liberty Teodoro⁹, Bryan M. Spann⁹, Laurel Beckett¹⁰, Danielle Harvey¹⁰, Evan Fletcher¹⁰, Owen Carmichael¹⁰, John Olichney¹⁰, Charles DeCarli¹⁰, Robert C. Green¹¹, Reisa A. Sperling¹¹, Keith A. Johnson¹¹, Gad Marshall¹¹, Meghan Frey¹¹, Barton Lane¹¹, Allyson Rosen¹¹, Jared Tinklenberg¹¹, Andrew J. Saykin¹², Tatiana M. Foroud¹², Li Shen¹², Kelley Faber¹², Sungeun Kim¹², Kwangsik Nho¹², Martin R. Farlow¹², AnnMarie Hake¹², Brandy R. Matthews¹², Scott Herring¹², Cynthia Hunt¹², John Morris¹³, Marc Raichle¹³, Davie Holtzman¹³, Nigel J. Cairns¹³, Erin Householder¹³, Lisa Taylor-Reinwald¹³, Beau Ances¹³, Maria Carroll¹³, Sue Leon¹³, Mark A. Mintun¹³, Stacy Schneider¹³, Angela Oliver¹³, Lisa Raudin¹⁴, Greg Sorensen¹⁵, Lew Kuller¹⁶, Chet Mathis¹⁶, Oscar L. Lopez¹⁶, MaryAnn Oakley¹⁶, Steven Paul¹⁷, Norman Relkin¹⁷, Gloria Chaing¹⁷, Lisa Raudin¹⁷, Peter Davies¹⁸, Howard Fillit¹⁹, Franz Hefti²⁰, M. Marcel Mesulam²¹, Diana Kerwin²¹, Marek-Marsel Mesulam²¹, Kristine Lipowski²¹, Chuang-Kuo Wu²¹, Nancy Johnson²¹, Jordan Grafman²¹, William Potter²², Peter Snyder²³, Adam Schwartz²⁴, Tom Montine²⁵, Elaine R. Peskind²⁶, Nick Fox²⁶, Paul Thompson²⁷, Liana Apostolova²⁷, Kathleen Tingus²⁷, Ellen Woo²⁷, Daniel H. S. Silverman²⁷, Po H. Lu²⁷, George Bartzokis²⁷, Robert A. Koeppe²⁸, Judith L. Heidebrink²⁸, Joanne L. Lord²⁸, Steven G. Potkin²⁸, Adrian Preda²⁸, Dana Nguyenv²⁸, Norm Foster²⁹, Eric M. Reiman³⁰, Kewei Chen³⁰, Adam Fleisher³⁰, Pierre Tariot³⁰, Stephanie Reeder³⁰, Steven Potkin³¹, Ruth A. Mulnard³¹, Gaby Thai³¹, Catherine Mc-Adams-Ortiz³¹, Neil Buckholtz³², John Hsiao³², Marylyn Albert³³, Marilyn Albert³³, Chiadi Onyike³³, Daniel D'Agostino³³, Stephanie Kielb³³, Donna M. Simpson³³, Richard Frank³⁴, Jeffrey Kaye³⁵, Joseph Quinn³⁵, Betty Lind³⁵, Raina Carter³⁵, Sara Dolen³⁵, Rachelle S. Doody³⁶, Javier Villanueva-Meyer³⁶, Munir Chowdhury³⁶, Susan Rountree³⁶, Mimi Dang³⁶, Yaakov Stern³⁶, Lawrence S. Honig³⁶, Karen L. Bell³⁶, Daniel Marson³⁷, Randall Griffith³⁷, David Clark³⁷, David Geldmacher³⁷, John Brockington³⁷, Erik Roberson³⁷, Hillel Grossman³⁸, Efe Mitsis³⁸, Leyla de Toledo-Morrell³⁹, Raj C. Shah³⁹, Debra Fleischman³⁹, Konstantinos Arfanakis³⁹, Ranjan Duara⁴⁰, Daniel Varon⁴⁰, Maria T. Greig⁴⁰, Peggy Roberts⁴⁰, James E. Galvin⁴¹, Brittany Cerbone⁴¹, Christina A. Michel⁴¹, Henry Rusinek⁴¹, Mony J. de Leon⁴¹, Lidia Glodzik⁴¹, Susan De Santi⁴¹, P. Murali Doraiswamy⁴², Jeffrey R. Petrella⁴², Terence Z. Wong⁴², Olga James⁴², Charles D. Smith⁴³, Greg Jicha⁴³, Peter Hardy⁴³, Partha Sinha⁴³, Elizabeth Oates⁴³, Gary Conrad⁴³, Anton P. Porsteinsson⁴⁴, Bonnie S. Goldstein⁴⁴, Kim Martin⁴⁴, Kelly M. Makino⁴⁴, M. Saleem Ismail⁴⁴, Connie Brand⁴⁴, Kyle Womack⁴⁵, Dana Mathews⁴⁵, Mary Quiceno⁴⁵, Ramon Diaz-Arrastia⁴⁵, Richard King⁴⁵, Myron Weiner⁴⁵, Kristen Martin-Cook⁴⁵, Michael DeVous⁴⁵, Allan I. Levey⁴⁶, James J. Lah⁴⁶, Janet S. Cellar⁴⁶, Jeffrey M. Burns⁴⁷, Heather S. Anderson⁴⁷, Russell H. Swerdlow⁴⁷, Neill R. Graf-Radford⁴⁸, Francine Parfitt⁴⁸, Tracy Kendall⁴⁸, Heather Johnson⁴⁸, Christopher H. van Dyck⁴⁹, Richard E. Carson⁴⁹, Martha G. MacAvoy⁴⁹, Howard Chertkow⁵⁰, Howard Bergman⁵⁰, Chris Hosein⁵⁰, Sandra Black⁵¹, Bojana Stefanovic⁵¹, Curtis Caldwell⁵¹, Ging-Yuek Robin Hsiung⁵², Howard Feldman⁵², Benita Mudge⁵², Michele Assaly⁵², Andrew Kertesz⁵³, John Rogers⁵³, Charles Bernick⁵³, Donna Munic⁵³, Andrew Kertesz⁵⁴, Andrew Kertesz⁵⁵, John Rogers⁵⁵, Elizabeth Finger⁵⁵, Stephen Pasternak⁵⁵, Irina Rachinsky⁵⁵, Dick Drost⁵⁵, Carl Sadowsky⁵⁶, Walter Martinez⁵⁶, Teresa Villena⁵⁶, Raymond Scott Turner⁵⁷, Kathleen Johnson⁵⁷, Brigid Reynolds⁵⁷, Marwan N. Sabbagh⁵⁸, Christine M. Belden⁵⁸, Sandra A. Jacobson⁵⁸, Sherye A. Sirrel⁵⁸, Neil Kowall⁵⁹, Ronald Killiany⁵⁹, Andrew E. Budson⁵⁹, Alexander Norbash⁵⁹, Patricia Lynn Johnson⁵⁹, Joanne Allard⁶⁰, Alan Lerner⁶¹, Paula Ogrocki⁶¹, Leon Hudson⁶¹, Smita Kittur⁶², Michael Borrie⁶³, T-Y Lee⁶³, Rob Bartha⁶³, Sterling Johnson⁶⁴, Sanjay Asthana⁶⁴, Cynthia M. Carlsson⁶⁴, J. Jay Fruehling⁶⁴, Sandra Harding⁶⁴, Vernice Bates⁶⁵, Horacio Capote⁶⁵, Michelle Rainka⁶⁵, Douglas W. Scharre⁶⁶, Maria Kataki⁶⁶, Anahita Adeli⁶⁶, Eric C. Petrie⁶⁶, Gail Li⁶⁶, Earl A. Zimmerman⁶⁷, Dzintra Celmins⁶⁷, Alice D. Brown⁶⁷, Godfrey D. Pearson⁶⁸, Karen Blank⁶⁸, Karen Anderson⁶⁸, Robert B. Santulli⁶⁹, Tamar J. Kitzmiller⁶⁹, Eben S. Schwartz⁶⁹, Kaycee M. Sink⁷⁰, Jef D. Williamson⁷⁰, Pradeep Garg⁷⁰, Franklin Watkins⁷⁰, Brian R. Ott⁷¹, Henry Querfurth⁷¹, Geoffrey Tremont⁷¹, Stephen Salloway⁷², Paul Malloy⁷², Stephen Correia⁷², Jacobo Mintzer⁷³, Kenneth Spicer⁷³, David Bachman⁷³, Dino Massoglia⁷³, Nunzio

Pomara⁷⁴, Raymundo Hernando⁷⁴, Antero Sarrael⁷⁴, Susan K. Schultz⁷⁵, Laura L. Boles Ponto⁷⁵, Hyungsub Shim⁷⁵, Karen Elizabeth Smith⁷⁵, Amanda Smith⁷⁶, Kristin Fargher⁷⁶, Balebail Ashok Raj⁷⁶, Karl Friedl⁷⁷, Jerome A. Yesavage⁷⁸, Joy L. Taylor⁷⁸ & Ansgar J. Furst⁷⁸

⁴UC San Francisco, California, USA. ⁵UC San Diego, San Diego, CA, USA. ⁶Mayo Clinic, Rochester, NY, USA. ⁷UC Berkeley, Berkeley, CA, USA. ⁸UPenn, Philadelphia, PA, USA. ⁹USC, Los Angeles, CA, USA. ¹⁰UC Davis, Davis, CA, USA. ¹¹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. ¹²Indiana University, Bloomington, IN, USA. ¹³Washington University St Louis, St Louis, MO, USA. ¹⁴Prevent Alzheimer's Disease, 2131, Rockville, MD, USA. ¹⁵Siemens, Munich, Germany. ¹⁶University of Pittsburg, Pittsburg, PA, USA. ¹⁷Cornell University, Ithaca, NY, USA. ¹⁸Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA. ¹⁹AD Drug Discovery Foundation, New York, NY, USA. ²⁰Acumen Pharmaceuticals, Livermore, CA, USA. ²¹Northwestern University, Evanston and Chicago, IL, USA. ²²National Institute of Mental Health, Rockville, MD, USA. ²³Brown University, Providence, RI, USA. ²⁴Eli Lilly, Indianapolis, IN, USA. ²⁵University of Washington, Seattle, WA, USA. ²⁶University of London, London, England, UK. ²⁷UCLA, Los Angeles, CA, USA. ²⁸University of Michigan, Ann Arbor, MI, USA. ²⁹University of Utah, Salt Lake, UT, USA. ³⁰Banner Alzheimer's Institute, Phoenix, AZ, USA. ³¹UC Irvine, Irvine, CA, USA. ³²National Institute on Aging, Bethesda, MD, USA. ³³Johns Hopkins University, Baltimore, MD, USA. ³⁴Richard Frank Consulting, Washington, DC, USA. ³⁵Oregon Health and Science University, Portland, OR, USA. ³⁶Baylor College of Medicine, Houston, TX, USA. ³⁷University of Alabama, Birmingham, AL, USA. ³⁸Mount Sinai School of Medicine, New York, NY, USA. ³⁹Rush University Medical Center, Chicago, IL, USA. ⁴⁰Wien Center, Miami, FL, USA. ⁴¹New York University, New York, NY, USA. ⁴²Duke University Medical Center, Durham, NC, USA. ⁴³University of Kentucky, Lexington, KY, USA. ⁴⁴University of Rochester Medical Center, Rochester, NY, USA. ⁴⁵University of Texas Southwestern Medical School, Dallas, TX, USA. ⁴⁶Emory University, Atlanta, GA, USA. ⁴⁷University of Kansas, Medical Center, Kansas City, KS, USA. ⁴⁸Mayo Clinic, Jacksonville, FL, USA. ⁴⁹Yale University School of Medicine, New Haven, CT, USA. ⁵⁰McGill University/Montreal-Jewish General Hospital, Montreal, QC, Canada. ⁵¹Sunnybrook Health Sciences, Toronto, ON, Canada. ⁵²U.B.C. Clinic for AD and Related Disorders, Vancouver, BC, Canada. ⁵³Cognitive Neurology-St Joseph's, London, ON, Canada. ⁵⁴Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. ⁵⁵St Joseph's Health Care, London, ON, Canada. ⁵⁶Premiere Research Institute, Palm Beach Neurology, Miami, FL, USA. ⁵⁷Georgetown University Medical Center, Washington, DC, USA. ⁵⁸Banner Sun Health Research Institute, Sun City, AZ, USA. ⁵⁹Boston University, Boston, MA, USA. ⁶⁰Howard University, Washington, DC, USA. ⁶¹Case Western Reserve University, Cleveland, OH, USA. ⁶²Neurological Care of CNY, Liverpool, NY, USA. ⁶³Parkwood Hospital, London, ON, Canada. ⁶⁴University of Wisconsin, Madison, WI, USA. ⁶⁵Dent Neurologic Institute, Amherst, NY, USA. ⁶⁶Ohio State University, Columbus, OH, USA. ⁶⁷Albany Medical College, Albany, NY, USA. ⁶⁸Hartford Hospital, Olin Neuropsychiatry Research Center, Hartford, CT, USA. ⁶⁹Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. ⁷⁰Wake Forest University Health Sciences, Winston-Salem, NC, USA. ⁷¹Rhode Island Hospital, Providence, RI, USA. ⁷²Butler Hospital, Providence, RI, USA. ⁷³Medical University South Carolina, Charleston, SC, USA. ⁷⁴Nathan Kline Institute, Orangeburg, NY, USA. ⁷⁵University of Iowa College of Medicine, Iowa City, IA, USA. ⁷⁶University of South Florida: USF Health Byrd Alzheimer's Institute, Tampa, FL, USA. ⁷⁷Department of Defense, Arlington, VA, USA. ⁷⁸Stanford University, Stanford, CA, USA.